22-24 November 2023
Fundação Calouste Gulbenkian, Lisboa, Portugal
22-24 November 2023
Fundação Calouste Gulbenkian, Lisboa, Portugal

22nd November

PL1 - Vanadium combinatorial therapy prevents loss of pancreatic β cell mass and function while ameliorating insulin resistance in type 2 diabetes – Debbie Crans

OL1 - Vanadium Acetylacetonate Complexes in the Treatment of Cancer - Rianne M. Lord 

OL2 - Lindqvist polyoxovanadate-peptides conjugates for cancer cell targeting - Mauro Carraro

IL1 - Substitution Kinetics, Albumin and Transferrin Affinities, and Hypoxia all Affect Biological Activities of Anticancer Vanadium(V) Complexes - Peter Lay –

IL2 - Ligand-specific structural features guide vanadium-dependent cell differentiation in adipogenesis - Thanos Salifoglou 

OL2 - Hydrazide-hydrazone: a linkage feature with a preponderant role in coordination chemistry and biological activity - Nádia Ribeiro

OL4 - Comparing the effects on Trypanosoma cruzi of heteroleptic oxidovanadium (V) complexes with 8-hydroxyquinoline derivatives - Gonzalo Scalese 

IL3 - Vanadium Effects on Lipid Peroxidation and Diseases - Manuel Aureliano

IL4 - Playing with Decavanadates and Tetravanadates: A Story Full of Surprises - Enrique González-Vergara 

OL5 - Exploring decavanadate salts with cationic dyes: tackling multidrug resistance and colorant adsorption - Juliana Missina 

OL6 - Vanadium complexes with hydrazone ligands and study of their biological interactions - Fernando Avecilla

OL7 - Multi-technique characterization and speciation of oxovanadium(IV) aqueous systems: interaction with 8-hydroxyquinoline-2-carboxylic acid and 6,7-dihydroxycoumarin - Matteo Marafante

IL5 - In vitro and in vivo biological activity of dipicolinate oxovanadium(IV) complexes - Alexandra R.Fernandes

OL8 - Development of two vanadium(V) Schiff-Base catecholate complexes: Relating stability and biological activity to structural modifications - Skyler Markham